Niimbl By Jeff Pinette Photography The national institute for innovation in manufacturing biopharmaceuticals (niimbl) is a public private partnership focused on advancing biopharmaceutical manufacturing, solving industry challenges, and developing the skilled workforce to meet industry’s needs. The national institute for innovation in manufacturing biopharmaceuticals (niimbl) is a public private partnership whose mission is to accelerate biopharmaceutical innovation, support the.
Niimbl Experience Niimbl Nist sponsored national institute for innovation in manufacturing biopharmaceuticals (niimbl) is dedicated to accelerating innovation in biopharmaceutical manufacturing of lifesaving therapeutics, solving industry challenges to enable cost effective and rapid manufacturing, and creating a well trained workforce for the field’s high paying jobs. Niimbl (the national institute for innovation in manufacturing biopharmaceuticals) is being formed to leverage a $70 million cost shared cooperative agreement with the national institute of standards and technology (nist) designed to innovate biomanufacturing in america. Niimbl is composed of 200 member organizations from academia, industry, government, and non profit organizations with a common goal to advance biopharmaceutical manufacturing. Niimbl’s mission is to advance the economic competitiveness of the us biopharmaceutical industry, to create jobs and improve the economy by accelerating the development and implementation of high impact biomanufacturing innovations that can be applied to current and future biopharmaceutical products, and to educate and train a world leading.
Niimbl Experience Niimbl Niimbl is composed of 200 member organizations from academia, industry, government, and non profit organizations with a common goal to advance biopharmaceutical manufacturing. Niimbl’s mission is to advance the economic competitiveness of the us biopharmaceutical industry, to create jobs and improve the economy by accelerating the development and implementation of high impact biomanufacturing innovations that can be applied to current and future biopharmaceutical products, and to educate and train a world leading. The national institute for innovation in manufacturing biopharmaceuticals (niimbl) is a public private partnership developed to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world leading biopharmaceutical manufacturing. Niimbl works to enhance innovative manufacturing capabilities and develop a world leading manufacturing workforce for the biopharmaceutical industry. Niimbl is the eleventh institute to join the manufacturing usa network and the first to be awarded under the 2014 bipartisan revitalize american manufacturing innovation (rami) act using an “open topic” competition. Niimbl is part of a diverse network of federally sponsored manufacturing innovation institutes, funded through a cooperative agreement with the national institute of standards and technology in the u.s. department of commerce.
Niimbl Announces New Funding Opportunities Niimbl The national institute for innovation in manufacturing biopharmaceuticals (niimbl) is a public private partnership developed to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world leading biopharmaceutical manufacturing. Niimbl works to enhance innovative manufacturing capabilities and develop a world leading manufacturing workforce for the biopharmaceutical industry. Niimbl is the eleventh institute to join the manufacturing usa network and the first to be awarded under the 2014 bipartisan revitalize american manufacturing innovation (rami) act using an “open topic” competition. Niimbl is part of a diverse network of federally sponsored manufacturing innovation institutes, funded through a cooperative agreement with the national institute of standards and technology in the u.s. department of commerce.
Comments are closed.